NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 20-cent third-quarter 2011 dividend on the company’s common stock, payable September 6, 2011, to shareholders of record at the close of business on August 5, 2011. The third-quarter 2011 cash dividend will be the 291st consecutive quarterly dividend paid by Pfizer.

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced today topline results of the Phase 3 ARISTOTLE trial of ELIQUIS®. In this study of patients with atrial fibrillation and at least one additional risk factor for stroke, ELIQUIS met the primary efficacy objective of non-inferiority to warfarin on the combined outcome of stroke (ischemic, hemorrhagic or unspecified type) and systemic embolism. In addition, ELIQUIS met the key

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that top-line results for Lyrica Study A0081107 – Central Neuropathic Pain Following Spinal Cord Injury – demonstrated that the study met its primary endpoint: positive efficacy in reducing Central Neuropathic Pain following Spinal Cord Injury with Lyrica (pregabalin) compared to placebo. Further analysis will be conducted on these initial results. Central Neuropathic Pain is a heterogeneous group of pain conditions initiated or

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Acura Pharmaceuticals Inc. (NASDAQ: ACUR) announce the marketing approval from the U.S. Food and Drug Administration (FDA) of OXECTATM (oxycodone HCl, USP) Tablets CII. OXECTA is indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate. OXECTA is the first immediate-release oxycodone HCl medicine that applies technology designed to discourage common methods of tampering ass

PEAPACK, N.J.--(BUSINESS WIRE)--Pfizer Injectables, part of Pfizer Inc.’s (NYSE: PFE) Established Products Business Unit, announced today the addition of doxorubicin hydrochloride injection, USP, to Pfizer Injectables’ growing portfolio of off-patent oncology products. In March 2011, the US Food and Drug Administration (FDA) approved the reintroduction of doxorubicin hydrochloride injection, USP, in medical grade Cytosafe® polypropylene vials in the following vial sizes: 5 mL (10 mg), 10 mL (20

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has received the 2011 CIO 100 award presented by CIO magazine. The 24th annual award program recognizes organizations around the world that exemplify the highest level of operational and strategic excellence in information technology (IT). "This year's CIO 100 awards draws well-deserved attention to companies that are not only innovating with IT but creating genuine business value as well," said Maryfran Johnson, editor in chief of C

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced its network of translational research partnerships, called the Centers for Therapeutic Innovation, has launched in Boston with Beth Israel Deaconess Medical Center, Boston University School of Medicine, Children’s Hospital Boston, Harvard University, Partners HealthCare, Tufts Medical Center, Tufts University, as well as University of Massachusetts Medical School in Worcester. These organizations follow on previously announced partnerships w

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) has announced the launch of a web site, “Migraines at Work” (http://migrainesatwork.com), to educate U.S. employers and the public regarding one of the world’s top 20 most disabling illnesses. According to the Migraine Research Foundation1, American employers lose 113 million workdays due to Migraines per year. The Migraine Research Foundation reported an estimated 30 million Americans suffer from Migraines—which is among the world’s top 20 most

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that it is conducting the first-ever randomized clinical trial under an investigational new drug (IND) application that manages study participation entirely using electronic tools and allows patients to participate in the clinical trial regardless of their proximity to clinical sites. The pilot project, initiated following review from the U.S. Food and Drug Administration (FDA), uses mobile phone and web-based technology to collect necessary

--(BUSINESS WIRE)--Pfizer What   Major announcement concerning new network for innovative science. News will also concern Pfizer’s real estate footprint in the City of Boston   Who Massachusetts Governor Deval Patrick, Boston Mayor Tom Menino, Pfizer senior executives, Boston’s top research and academic leaders   When Wednesday, June 8, 2011, 2:00 p.m.Interviews immediately following announcement   Where Center for Life Science BostonLongwood Medical Area3 Blackfan Circle,Boston, Mass.Ground flo